| General Information of Drug Metabolite (DM) (ID: DM002214) |
| DM Name |
Niraparib metabolite M10
|
| Structure |
|
|
3D MOL is unavailable
|
2D MOL is unavailable
|
|
|
|
|
|
|
|
| Full List of Drug-Metabolizing Enzyme (DME) Related to This DM |
| DME(s) Producing This DM through Metabolism |
| DME Name |
DME ID |
Reactant |
Reaction |
Related Drug |
REF |
|
UDP-glucuronyltransferase (UGT)
|
DMEN064
|
| Unclear - Unclear |
Niraparib
|
[1] , [2] |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Full List of Drug(s) That Produce This DM By Metabolism |
| Niraparib |
DR1164
|
Approved |
Ovarian cancer |
|
|
| References |
| 1 |
Human mass balance study and metabolite profiling of (14)C-niraparib, a novel poly(ADP-Ribose) polymerase (PARP)-1 and PARP-2 inhibitor, in patients with advanced cancer Invest New Drugs. 2017 Dec;35(6):751-765. doi: 10.1007/s10637-017-0451-2.
|
| 2 |
P-Glycoprotein (ABCB1/MDR1) Controls Brain Penetration and Intestinal Disposition of the PARP1/2 Inhibitor Niraparib. Mol Pharm. 2021 Dec 6;18(12):4371-4384. doi: 10.1021/acs.molpharmaceut.1c00553.
|
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.
